Intravenous belimumab utilisation*
| Intravenous belimumab utilisation (n=1879) | |
| Initiation period | |
| Administrations, mean (SD) | 2.2 (0.8) |
| Categories, n (%) | |
| 1 administration | 449 (23.9) |
| 2 administrations | 619 (32.9) |
| ≥3 administrations | 811 (43.2) |
| Days between administrations, mean (SD) | 15.9 (5.2) |
| Maintenance period | |
| Administrations, mean (SD) | 3.1 (2.0) |
| Days between administrations, mean (SD) | 30.4 (10.0) |
| Total 6-month period | |
| Administrations, mean (SD) | 5.3 (2.4) |
| ≥3 administrations, n (%) | 1547 (82.3) |
| Days to third administration, mean (SD) | 46.3 (27.3) |
| Discontinuation, n (%) | 492 (26.2) |
*Patients with SLE identified via the IBM MarketScan Commercial Claims and Encounters Database (2010–2015) with ≥1 belimumab intravenous infusion during 2011–2015.